Journal of Pharmacokinetics & Experimental Therapeutics

Joseph, J Pharmacokinet Exp Ther 2023, 7:2

Review Article Open Access

Keywords: Ulcerative colitis; Monoclonal antibody; Pharmacokinetic; erapeutic e ect

Introduction

Chronic gastrointestinal in ammatory disease called ulcerative

the blood. Descriptive statistics were used to compile the results of all studies provided here; formal statistical hypothesis testing was not done. In order to estimate the real proportion of paediatric patients who had a clinical response at week 8 with a 95% con dence interval, a sample size of 60 patients was intended. Based on the aggregated clinical response rate seen among all randomised adult patients with UC receiving in iximab 5 mg/kg in 2 independent studies, this sample size estimate used a clinical response rate of 67% at week 8. All treated participants were used in the analyses of the main endpoint and all other e cacy endpoints assessed at or before the week 8 visit. Patients who were randomised at week 8 served as the basis for analyses of e ectiveness outcomes assessed beyond that time [7].

Pharmacodynamics

e activation of the pro-in ammatory cascade signalling is interfered with by in iximab. In amed cell in ltration into in ammatory areas has been demonstrated to be decreased by in iximab. e expression of molecules involved in cellular adhesion, such as E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), chemoattraction, such as IL-8 and monocyte chemotactic protein (MCP-1), and tissue degradation, such as matrix metalloproteinase (MMP) 1 and 3, is also suppressed [8].

Result and Discussion

Parental resistance to enrolling children in clinical trials, a lack of paediatric investigators with the necessary training, children's particular vulnerabilities, and ethical or methodological di culties associated with conducting clinical trials in a paediatric population are just a few of the well-documented di culties of conducting paediatric trials. In addition to these di culties, there are relatively less juvenile patients with in ammatory bowel disease (UC) compared to the equivalent adult group. Due to these restrictions, children clinical trials have a smaller patient pool than adult studies. As a result, it is crucial to make the most of the information gleaned from paediatric studies by combining it with adult research on the condition of interest. e United States Food and Medication Administration rst explicitly promoted the idea of extending e ectiveness data from adult to paediatric populations in 1994 when establishing and evaluating paediatric drug development programmes [9].

Speci c strategy

e speci c strategy for extrapolating from adults to children is dependent on important presumptions about the history of the relevant disease and how it responds to intervention, as well as the exposure-response relationship between the intervention and e ectiveness. Generally speaking, extrapolating e cacy or other data from an adult population to a paediatric population can increase access to treatments already available to the adult population, improve the e ciency of paediatric drug development, and ensure that these medications are used properly in children. As a result, in the same research, it was expected that systemic in iximab exposure in paediatric patients aged 2 to 6 years would be around 40% lower than that in adults.

Weight and in iximab

is di erence is due to the nonlinear relationship between body weight and in iximab clearance combined with the linear dosing regimen (mg/kg), which results in a tendency toward lower serum in iximab exposure in children with lower body weights. Age was not a signi cant covariate once body weight was taken into account in this integrated analysis. ese studies may point to the necessity for paediatric patients with UC who are less than 6 years old to receive a larger in iximab dosage (mg/kg) in order to obtain serum in iximab concentrations in this age group that are equivalent to those seen in older children and adults. In view of reports of lower e cacy of the 5-mg/kg in iximab regimen in younger children with in ammatory bowel disease, more research may be required to examine the e ects of possible changes in serum in iximab concentration on e cacy in this younger age group [10].

Conclusion

An induction regimen of 5 mg/kg administered as an intravenous infusion at weeks 0, 2, and 6 followed by maintenance infusions of 5 mg/kg in iximab q8w appears to be appropriate for the treatment of UC in paediatric patients, according to an analysis of the pharmacokinetic, e cacy, and safety data from C0168T72 and supportive data from adult patients with UC. is analysis showed comparable pharmacokinetics and exposure-response between the paediatric and adult patients. To more fully understand the pharmacokinetics of in iximab in younger paediatric patients with UC, more research on the drug's pharmacokinetics and exposure-response relationships in paediatric patients with UC younger than 6 years may be necessary.

Acknowledgement

None

Con ict of Interest

Author declares no con ict of interest.

References

1. Stone NR, Bicanic T, Salim R, Hope W (2016) Liposomal Amphotericin B (AmBisome (®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs 76:485-500.
2. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, et al. (2019) Pharmacogenomics. Lancet 394:521-532.
3. Miranda Furtado CL, Silva Santos RD, Furtado GP (2019) Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics 14:1164-1176.
4. Currie GM (2018) Pharmacology, Part 2: Introduction to Pharmacokinetics J Nucl Med Technol 46-3:221-230.
5. Whirl-Carrillo M, Mc-Donagh EM, Hebert JM, Gong L, Sangkuhl K, et al. (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414-417.
6. Kesik-Brodacka M. (2018) Progress in biopharmaceutical development. Biotechnol Appl Biochem 65:306-322.
7. Burk JA, Blumenthal SA, Maness EB (2018) Neuropharmacology of attention. Eur J Pharmacol 835:162-168.
8. McCune JS, Bemer MJ, Long-Boyle J (2016) Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. Clin Pharmacokinet 5:551-593.
9. Calvo E, Walko C, Dees EC, Valenzuela B (2016) Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies. Am Soc Clin Oncol Educ Book 35:175-184
10. Venturella G, Ferraro V, Cirlincione F, Gargano ML (2021) Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials. Int J Mol Sci 22:634.